share_log

Applied Therapeutics Faces Uncertainty After US FDA Rejects NDA for Govorestat in Galactosemia, UBS Says

Applied Therapeutics Faces Uncertainty After US FDA Rejects NDA for Govorestat in Galactosemia, UBS Says

应用治疗在美国FDA拒绝Govorestat针对半乳糖血症的申请后面临不确定性,瑞士银行表示
MT Newswires ·  2024/12/02 17:16

Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发